grant
Understanding B-Lactam Resistance in Acinetobacter baumannii
Organization CASE WESTERN RESERVE UNIVERSITYLocation CLEVELAND, UNITED STATESPosted 1 Aug 2007Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY2026A baumanniA baumanniiA. baumanniA. baumanniiA.baumanniiAccelerationAcinetobacter baumanniAcinetobacter baumanniiActive SitesAddressAnimal TestingAntibiotic AgentsAntibiotic DrugsAntibioticsAwarenessBacteriaBacteria resistanceBacteria resistantBacterial resistantBeta-Lactam resistantBindingBinding SitesBoronic AcidsCOVID crisisCOVID epidemicCOVID pandemicCOVID-19 crisisCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 pandemicCOVID-19 periodCOVID-19 public health crisisCOVID-19 yearsCarbapenem-resistant AcinetobacterCategoriesCell BodyCellsCenters for Disease ControlCenters for Disease Control and PreventionCenters for Disease Control and Prevention (U.S.)ChemistryClinicalCollectionColorCombining SiteCyclicityDrug resistanceDrugsElectronicsEnzyme GeneEnzymesExhibitsFe elementFundingG24 proteinGenesGenetic DiversityGenetic VariationGoalsHealth CareHealth Care SystemsHigh Throughput AssayHospitalsHot SpotHydrolysisImipemideImipenemInfectionIntensive Care UnitsIonsIronKineticsL-SerineLactamaseLung infectionsMediatingMedicalMedicationMedicinal ChemistryMiscellaneous AntibioticModificationMolecularMolecular InteractionMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsMultienzyme ComplexesMureinN-FormimidoylthienamycinNatureOrganismPathway interactionsPenetrationPeptidoglycanPeriodicityPeriplasmic SpacePharmaceutic ChemistryPharmaceutical ChemistryPharmaceutical PreparationsProductionPropertyReactionReactive SiteResistanceRhythmicitySARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 pandemicSARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSerineSevere Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 pandemicSideUnited States Centers for Disease ControlUnited States Centers for Disease Control and PreventionVDAC1VDAC1 geneZincZn elementacylamidaseacylaseamidaseb lactam resistanceb-lactam resistantbacterial resistancebeta lactam hydrolasebeta-Lactam Resistancebeta-Lactamasebeta-Lactamhydrolasecandidate identificationcellular targetingcoronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19 global pandemiccoronavirus disease-19 pandemicdesigndesigningdrug resistantdrug/agentelectronicelectronic deviceenzyme complexfunctional groupgene producthigh throughput screeningimprovedin vitro activityinhibitorinsightinterdisciplinary approachiterative designliving systemmolecular modelingmultidisciplinary approachnew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapyoverexpressoverexpressionpathogenpathwayperiplasmpore forming proteinporinpulmonary infectionsresistance against beta lactamsresistance to Bacteriaresistance to Bacterialresistance to Drugresistance to b lactamresistance to beta-lactamresistance to β-Lactamresistantresistant to Bacteriaresistant to Bacterialresistant to Drugresistant to b lactamresistant to beta-lactamresistant to β-Lactamscaffoldscaffoldingsevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsmall moleculesuccesstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentβ-Lactam Resistanceβ-Lactam resistantβ-Lactamase
Description preview
The Centers for Disease Control and Prevention (CDC) designated Carbapenem-Resistant Acinetobacter
baumannii (CRAb) an “urgent threat pathogen” for which novel therapies are desperately needed. The current
COVID-19 pandemic has only accelerated the emergence of CRAb in medical intensive care units and hospitals,
creating a parallel health care…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click